The synergistic use of computation, chemistry and biology to discover novel peptide-based drugs: The time is right

Current Pharmaceutical Design

Volumn 16, Issue 5, 2010, Pages 567-582

  Audie, J ^a,b   Boyd, C ^c  

^a CMD Bioscience   (United States)

^b USA   (United States)

^c NONE

Author keywords

Combinatorial; Docking; Peptides; Phage display; Protein protein; Structure based drug design; Therapeutics; Virtual screening

Indexed keywords

BETA BREAKER PEPTIDE; CALCITONIN; CASPASE 3; CONOTOXIN; DEGARELIX; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; EXENDIN 4; FIRMAGON; GLUCAGON LIKE PEPTIDE 1; GONADORELIN; GRANULOCYTE COLONY STIMULATING FACTOR; ICATIBANT; INSULIN; LIRAGLUTIDE; MEPACT; MIFAMURTIDE; OMEGA CONOTOXIN MVIIA; OPIATE PEPTIDE; PEPTIDE DERIVATIVE; PEPTIDE YY [3-36]; POLYPEPTIDE ANTIBIOTIC AGENT; PROTIRELIN; RAF PROTEIN; RAS PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ANGIONEUROTIC EDEMA; BINDING SITE; BIOCHEMISTRY; BLOOD BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; CHRONIC PAIN; CLINICAL TRIAL; COMPUTER MODEL; CYCLIZATION; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG INDUSTRY; DRUG PENETRATION; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; LIPOSOMAL DELIVERY; METHYLATION; MOLECULAR DOCKING; MOLECULAR MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOSARCOMA; PAIN; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SCORING SYSTEM; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 77949472320     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790361425     Document Type: Review

References (152)

1. Janice Reichert PS, Abraham Seckler, Pierre Riviere, Andre Tartar, and Michael K. Dunn. Development Trends for Peptide Therapeutics 2008.
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3(8): 711-5.
3. Ahlborn H, Henderson S, Davies N. No immediate pain relief for the pharmaceutical industry. Curr Opin Drug Discov Dev 2005; 8(3): 384-91.
4. Kola I. The state of innovation in drug development. Clin Pharmacol Ther 2008; 83(2): 227-30.
5. Ladner RC, Sato AK, Gorzelany J, de Souza M. Phage displayderived peptides as therapeutic alternatives to antibodies. Drug Discov Today 2004; 9(12): 525-9.
6. Banks WA. Delivery of peptides to the brain: emphasis on therapeutic development. Biopolymers 2008; 90(5): 589-94.
7. Banks WA. The CNS as a target for peptides and peptide-based drugs. Expert Opin Drug Deliv 2006; 3(6): 707-12.
8. Egleton RD, Davis TP. Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx 2005; 2(1): 44-53.
9. Witt KA, Davis TP. CNS drug delivery: opioid peptides and the blood-brain barrier. AAPS J 2006; 8(1): E76-88.
10. Falciani C, Lozzi L, Pini A, Bracci L. Bioactive peptides from libraries. Chem Biol 2005; 12(4): 417-26.
11. Shrivastava A, Nunn AD, Tweedle MF. Designer peptides: learning from nature. Curr Pharm Des 2009; 15(6): 675-81.
12. McGregor DP. Discovering and improving novel peptide therapeutics. Curr Opin Pharmacol 2008; 8(5): 616-9.
13. Watt PM. Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Nat Biotechnol 2006; 24(2): 177-83.
14. Rubinstein M, Niv MY. Peptidic modulators of protein-protein interactions: progress and challenges in computational design. Biopolymers 2009; 91(7): 505-13.
15. Sillerud LO, Larson RS. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. Curr Protein Pept Sci 2005; 6(2): 151-69.
16. Lewis RJ, Garcia ML. Therapeutic potential of venom peptides. Nat Rev Drug Discov 2003; 2(10): 790-802.
17. Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs: barriers and developments. Bio Drugs 2005; 19(3): 165-77.
18. Gentilucci L, Tolomelli A, Squassabia F. Peptides and peptidomimetics in medicine, surgery and biotechnology. Curr Med Chem 2006; 13(20): 2449-66.
19. Hruby VJ. Designing peptide receptor agonists and antagonists. Nat Rev Drug Discov 2002; 1(11): 847-58.
20. Hruby VJ. Keynote speech. 21st American peptide symposium: breaking away. Bloomington, Indiana: None 2009.
21. Zorko M, Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev 2005; 57(4): 529-45.
22. Palffy R, Gardlik R, Behuliak M, Kadasi L, Turna J, Celec P. On the physiology and pathophysiology of antimicrobial peptides. Mol Med 2009; 15(1-2): 51-9.
23. Reddy KV, Yedery RD, Aranha C. Antimicrobial peptides: premises and promises. Int J Antimicrob Agents 2004; 24(6): 536-47.
24. Ganapathy V, Miyauchi S. Transport systems for opioid peptides in mammalian tissues. AAPS J 2005; 7(4): E852-6.
25. Lucchese G, Stufano A, Trost B, Kusalik A, Kanduc D. Peptidology: short amino acid modules in cell biology and immunology. Amino Acids 2007; 33(4): 703-7.
26. Ja WW, Wiser O, Austin RJ, Jan LY, Roberts RW. Turning G proteins on and off using peptide ligands. ACS Chem Biol 2006; 1(9): 570-4.
27. Souroujon MC, Mochly-Rosen D. Peptide modulators of protein-protein interactions in intracellular signaling. Nat Biotechnol 1998; 16(10): 919-24.
28. Ferro ES, Hyslop S, Camargo AC. Intracellullar peptides as putative natural regulators of protein interactions. J Neurochem 2004; 91(4): 769-77.
29. Cunha FM, Berti DA, Ferreira ZS, Klitzke CF, Markus RP, Ferro ES. Intracellular peptides as natural regulators of cell signaling. J Biol Chem 2008; 283(36): 24448-59.
30. Dunican DJ, Doherty P. Designing cell-permeant phosphopeptides to modulate intracellular signaling pathways. Biopolymers 2001; 60(1): 45-60.
31. Dunican DJ, Williams EJ, Howell FV, Doherty P. Selective inhibition of fibroblast growth factor (FGF)-stimulated mitogenesis by a FGF receptor-1-derived phosphopeptide. Cell Growth Differ 2001; 12(5): 255-64.
32. Churchill EN, Qvit N, Mochly-Rosen D. Rationally designed peptide regulators of protein kinase C. Trends Endocrinol Metab 2009; 20(1): 25-33.
33. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004; 3(4): 301-17.
34. Loregian A, Palu G. Disruption of protein-protein interactions: towards new targets for chemotherapy. J Cell Physiol 2005; 204(3): 750-62.
35. Gerrard JA, Hutton CA, Perugini MA. Inhibiting protein-protein interactions as an emerging paradigm for drug discovery. Mini Rev Med Chem 2007; 7(2): 151-7.
36. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95(23): 13363-83.
37. Zaloga GP, Siddiqui RA. Biologically active dietary peptides. Mini Rev Med Chem 2004; 4(8): 815-21.
38. Touhara K. Molecular biology of peptide pheromone production and reception in mice. Adv Genet 2007; 59: 147-71.
39. Beglinger C, Poller B, Arbit E, Ganzoni C, Gass S, Gomez-Orellana I, et al. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin Pharmacol Ther 2008; 84(4): 468-74.
40. Foltz M, Meynen EE, Bianco V, van Platerink C, Koning TM, Kloek J. Angiotensin converting enzyme inhibitory peptides from a lactotripeptide- enriched milk beverage are absorbed intact into the circulation. J Nutr 2007; 137(4): 953-8.
41. Hernandez-Ledesma B, Hsieh CC, de Lumen BO. Lunasin, a novel seed peptide for cancer prevention. Peptides 2009; 30(2): 426-30.
42. Banks WA. Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease. BMC Neurosci 2008; 9(Suppl 3): S2.
43. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov 2003; 2(4): 289-95.
44. Verma C, Seebah S, Low SM, Zhou L, Liu SP, Li J, et al. Defensins: antimicrobial peptides for therapeutic development. Biotechnol J 2007; 2(11): 1353-9.
45. De Coupade C, Fittipaldi A, Chagnas V, Michel M, Carlier S, Tasciotti E, et al. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem J 2005; 390(Pt 2): 407-18.
46. Stefanidakis M, Koivunen E. Peptide-mediated delivery of therapeutic and imaging agents into mammalian cells. Curr Pharm Des 2004; 10(24): 3033-44.
47. Wangler C, Buchmann I, Eisenhut M, Haberkorn U, Mier W. Radiolabeled peptides and proteins in cancer therapy. Protein Pept Lett 2007; 14(3): 273-9.
48. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25(8): 1398-404.
49. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 1994; 35(Suppl 3): S1-4.
50. Witt KA, Huber JD, Egleton RD, Roberts MJ, Bentley MD, Guo L, et al. Pharmacodynamic and pharmacokinetic characterization of poly(ethylene glycol) conjugation to met-enkephalin analog [DPen2, D-Pen5]-enkephalin (DPDPE). J Pharmacol Exp Ther 2001; 298(2): 848-56.
51. Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 2004; 24(3): 357-97.
52. Kumar TR, Soppimath K, Nachaegari SK. Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol 2006; 7(4): 261-76.
53. Zhang G, Han B, Lin X, Wu X, Yan H. Modification of antimicrobial peptide with low molar mass poly(ethylene glycol). J Biochem 2008; 144(6): 781-8.
54. Marschutz MK, Zauner W, Mattner F, Otava A, Buschle M, Bernkop-Schnurch A. Improvement of the enzymatic stability of a cytotoxic T-lymphocyte-epitope model peptide for its oral administration. Peptides 2002; 23(10): 1727-33.
55. Jain A, Jain SK. PEGylation: an approach for drug delivery. A review. Crit Rev Ther Drug Carrier Syst 2008; 25(5): 403-47.
56. Nakane S, Kakumoto M, Yukimatsu K, Chien YW. Oramucosal delivery of LHRH: pharmacokinetic studies of controlled and enhanced transmucosal permeation. Pharm Dev Technol 1996; 1(3): 251-9.
57. Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag 2009; 5(1): 199-211.
58. Pan CQ, Buxton JM, Yung SL, Tom I, Yang L, Chen H, et al. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J Biol Chem 2006; 281(18): 12506-15.
59. Elmagbari NO, Egleton RD, Palian MM, Lowery JJ, Schmid WR, Davis P, et al. Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. J Pharmacol Exp Ther 2004; 311(1): 290-7.
60. Adessi C, Frossard MJ, Boissard C, Fraga S, Bieler S, Ruckle T, et al. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J Biol Chem 2003; 278(16): 13905-11.
61. Hamamoto K, Kida Y, Zhang Y, Shimizu T, Kuwano K. Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. Microbiol Immunol 2002; 46(11): 741-9.
62. Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, et al. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci USA 2007; 104(31): 12772-7.
63. Werle M, Takeuchi H. Chitosan-aprotinin coated liposomes for oral peptide delivery: Development, characterisation and in vivo evaluation. Int J Pharm 2009; 370(1-2): 26-32.
64. Petrus AK, Fairchild TJ, Doyle RP. Traveling the vitamin B12 pathway: oral delivery of protein and peptide drugs. Angew Chem Int Ed Engl 2009; 48(6): 1022-8.
65. Petrus AK, Allis DG, Smith RP, Fairchild TJ, Doyle RP. Exploring the implications of vitamin B12 conjugation to insulin on insulin receptor binding. Chem Med Chem 2009; 4(3): 421-6.
66. Petrus AK, Vortherms AR, Fairchild TJ, Doyle RP. Vitamin B12 as a carrier for the oral delivery of insulin. Chem Med Chem 2007; 2(12): 1717-21.
67. Oh Y, Varmanen P, Han XY, Bennett G, Xu Z, Lu T, et al. Lactobacillus plantarum for oral peptide delivery. Oral Microbiol Immunol 2007; 22(2): 140-4.
68. Chatterjee J, Gilon C, Hoffman A, Kessler H. N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res 2008; 41(10): 1331-42.
69. Chatterjee J, Ovadia O, Gilon C, Hoffman A, Mierke D, Kessler H. N-methylated cyclic pentapeptides as template structures. Adv Exp Med Biol 2009; 611: 109-10.
70. Craik DJ, Clark RJ, Daly NL. Potential therapeutic applications of the cyclotides and related cystine knot mini-proteins. Expert Opin Investig Drugs 2007; 16(5): 595-604.
71. Walensky LD, Pitter K, Morash J, Oh KJ, Barbuto S, Fisher J, et al. A stapled BID BH3 helix directly binds and activates BAX. Mol Cell 2006; 24(2): 199-210.
72. Clark RJ, Fischer H, Dempster L, Daly NL, Rosengren KJ, Nevin ST, et al. Engineering stable peptide toxins by means of backbone cyclization: stabilization of the οα-conotoxin MII. Proc Natl Acad Sci USA 2005; 102(39): 13767-72.
73. Henry CM. Breaching barriers. Chem Eng News 2003; 25: 35-43.
74. Sawyer TK. AILERON Therapeutics. Chem Biol Drug Des 2009; 73(1): 3-6.
75. Staff. Watching peptide drugs grow up. Chem Eng News 2005; 4: 17-24.
76. Parmar H. Therapeutic peptides in Europe: finding the opportunities. Frost and Sullivan report 2004.
77. Schuster D, Laggner C, Langer T. Why drugs fail - a study on side effects in new chemical entities. Curr Pharm Des 2005; 11(27): 3545-59.
78. Hodgson J. ADMET - turning chemicals into drugs. Nat Biotechnol 2001; 19(8): 722-6.
79. Agarwal S, Boddu SH, Jain R, Samanta S, Pal D, Mitra AK. Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor. Int J Pharm 2008; 359(1-2): 7-14.
80. Ezra A, Hoffman A, Breuer E, Alferiev IS, Monkkonen J, El Hanany-Rozen N, et al. A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem 2000; 43(20): 3641-52.
81. Nielsen CU, Brodin B. Di/tri-peptide transporters as drug delivery targets: regulation of transport under physiological and pathophysiological conditions. Curr Drug Targets 2003; 4(5): 373-88.
82. Costa-Junior HM, Suetsugu MJ, Krieger JE, Schechtman D. Specific modulation of protein kinase activity via small peptides. Regul Pept 2009; 153(1-3): 11-8.
83. Mourez M, Collier RJ. Use of phage display and polyvalency to design inhibitors of protein-protein interactions. Methods Mol Biol 2004; 261: 213-28.
84. Rao GS, Bhatnagar S. In silico structure-based design of a potent, mutation resilient, small peptide inhibitor of HIV-1 reverse transcriptase. J Biomol Struct Dyn 2003; 21(2): 171-8.
85. Landon LA, Zou J, Deutscher SL. Is phage display technology on target for developing peptide-based cancer drugs? Curr Drug Discov Technol 2004; 1(2): 113-32.
86. Ricklin D, Lambris JD. Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 2008; 632: 273-92.
87. Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis V, Kramer S, et al. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin Cancer Res 2005; 11(1): 139-46.
88. Pini A, Giuliani A, Falciani C, Runci Y, Ricci C, Lelli B, et al. Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob Agents Chemother 2005; 49(7): 2665-72.
89. Szardenings M. Phage display of random peptide libraries: applications, limits, and potential. J Recept Signal Transduct Res 2003; 23(4): 307-49.
90. Su JL, Lai KP, Chen CA, Yang CY, Chen PS, Chang CC, et al. A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Res 2005; 65(11): 4827-35.
91. Mezo AR, McDonnell KA, Hehir CA, Low SC, Palombella VJ, Stattel JM, et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proc Natl Acad Sci USA 2008; 105(7): 2337-42.
92. Lam KS. Application of combinatorial library methods in cancer research and drug discovery. Anticancer Drug Des 1997; 12(3): 145-67.
93. Roof RA, Sobczyk-Kojiro K, Turbiak AJ, Roman DL, Pogozheva ID, Blazer LL, et al. Novel peptide ligands of RGS4 from a focused one-bead, one-compound library. Chem Biol Drug Des 2008; 72(2): 111-9.
94. Wavreille AS, Garaud M, Zhang Y, Pei D. Defining SH2 domain and PTP specificity by screening combinatorial peptide libraries. Methods 2007; 42(3): 207-19.
95. Joo SH, Pei D. Synthesis and screening of support-bound combinatorial peptide libraries with free C-termini: determination of the sequence specificity of PDZ domains. Biochemistry 2008; 47(9): 3061-72.
96. Zhang Y, Zhou S, Wavreille AS, DeWille J, Pei D. Cyclic peptidyl inhibitors of Grb2 and tensin SH2 domains identified from combinatorial libraries. J Comb Chem 2008; 10(2): 247-55.
97. Mersich C, Jungbauer A. Generation of bioactive peptides by biological libraries. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 861(2): 160-70.
98. Gram H, Schmitz R, Zuber JF, Baumann G. Identification of phosphopeptide ligands for the Src-homology 2 (SH2) domain of Grb2 by phage display. Eur J Biochem 1997; 246(3): 633-7.
99. Gorris HH, Bade S, Rockendorf N, Albers E, Schmidt MA, Franek M, et al. Rapid profiling of peptide stability in proteolytic environments. Anal Chem 2009; 81(4): 1580-6.
100. Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov 2002; 1(11): 882-94.
101. Lyne PD. Structure-based virtual screening: an overview. Drug Discov Today 2002; 7(20): 1047-55.
102. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004; 3(11): 935-49.
103. Kapetanovic IM. Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact 2008; 171(2): 165-76.
104. Anderson AC. The process of structure-based drug design. Chem Biol 2003; 10(9): 787-97.
105. Shoichet BK. Virtual screening of chemical libraries. Nature 2004; 432(7019): 862-5.
106. Desmet J, Wilson IA, Joniau M, De Maeyer M, Lasters I. Computation of the binding of fully flexible peptides to proteins with flexible side chains. FASEB J 1997; 11(2): 164-72.
107. Rosenfeld R, Zheng Q, Vajda S, DeLisi C. Flexible docking of peptides to class I major-histocompatibility-complex receptors. Genet Anal 1995; 12(1): 1-21.
108. Zhou Y, Abagyan R. How and why phosphotyrosine-containing peptides bind to the SH2 and PTB domains. Fold Des 1998; 3(6): 513-22.
109. Liu Z, Dominy BN, Shakhnovich EI. Structural mining: selfconsistent design on flexible protein-peptide docking and transferable binding affinity potential. J Am Chem Soc 2004; 126(27): 8515-28.
110. Gautham PAPaN. A new peptide docking strategy using a mean field technique with mutually orthogonal Latin square sampling. J Comput Aided Mol Des 2008; 22(11): 815-29.
111. Kurcinski M, Kolinski A. Steps towards flexible docking: modeling of three-dimensional structures of the nuclear receptors bound with peptide ligands mimicking co-activators' sequences. J Steroid Biochem Mol Biol 2007; 103(3-5): 357-60.
112. Hetenyi C, van der Spoel D. Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci 2002; 11(7): 1729-37.
113. Yoshimori A, Takasawa R, Tanuma S. A novel method for evaluation and screening of caspase inhibitory peptides by the amino acid positional fitness score. BMC Pharmacol 2004; 4: 7.
114. Rajakrishnan V, Manoj VR, Subba Rao G. Computer-aided, rational design of a potent and selective small peptide inhibitor of cyclooxygenase 2 (COX2). J Biomol Struct Dyn 2008; 25(5): 535-42.
115. Rao GS, Ramachandran MV, Bajaj JS. In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach. J Biomol Struct Dyn 2006; 23(4): 377-84.
116. Yagi Y, Terada K, Noma T, Ikebukuro K, Sode K. In silico panning for a non-competitive peptide inhibitor. BMC Bioinformatics 2007; 8: 11.
117. Budin N, Ahmed S, Majeux N, Caflisch A. An evolutionary approach for structure-based design of natural and non-natural peptidic ligands. Comb Chem High Throughput Screen 2001; 4(8): 661-73.
118. Zeng J, Nheu T, Zorzet A, Catimel B, Nice E, Maruta H, et al. Design of inhibitors of Ras - Raf interaction using a computational combinatorial algorithm. Protein Eng 2001; 14(1): 39-45.
119. Sood VD, Baker D. Recapitulation and design of protein binding peptide structures and sequences. J Mol Biol 2006; 357(3): 917-27.
120. Zhang R, Wei DQ, Du QS, Chou KC. Molecular modeling studies of peptide drug candidates against SARS. Med Chem 2006; 2(3): 309-14.
121. Liu FF, Dong XY, Wang T, Sun Y. Rational design of peptide ligand for affinity chromatography of tissue-type plasminogen activator by the combination of docking and molecular dynamics simulations. J Chromatogr A 2007; 1175(2): 249-58.
122. Espinoza-Fonseca LM, Trujillo-Ferrara JG. Fully flexible docking models of the complex between α7 nicotinic receptor and a potent heptapeptide inhibitor of the β-amyloid peptide binding. Bioorg Med Chem Lett 2006; 16(13): 3519-23.
123. Parthiban M, Shanmughavel P. Three dimensional modeling of Nterminal region of galanin and its interaction with the galanin receptor. Bioinformation 2007; 2(3): 119-25.
124. Walters DE, Hellekant G. Interactions of the sweet protein brazzein with the sweet taste receptor. J Agric Food Chem 2006; 54(26): 10129-33.
125. Yi H, Qiu S, Cao Z, Wu Y, Li W. Molecular basis of inhibitory peptide maurotoxin recognizing Kv1.2 channel explored by ZDOCK and molecular dynamic simulations. Proteins 2008; 70(3): 844-54.
126. Kaur H, Garg A, Raghava GP. PEPstr: a de novo method for tertiary structure prediction of small bioactive peptides. Protein Pept Lett 2007; 14(7): 626-31.
127. Thomas A, Deshayes S, Decaffmeyer M, Van Eyck MH, Charloteaux B, Brasseur R. Prediction of peptide structure: how far are we? Proteins 2006; 65(4): 889-97.
128. Nicosia G, Stracquadanio G. Generalized pattern search algorithm for Peptide structure prediction. Biophys J 2008; 95(10): 4988-99.
129. Maupetit J, Derreumaux P, Tuffery P. PEP-FOLD: an online resource for de novo peptide structure prediction. Nucleic Acids Res 2009; 37(Web Server issue): W498-503.
130. Shtatland T, Guettler D, Kossodo M, Pivovarov M, Weissleder R. PepBank - a database of peptides based on sequence text mining and public peptide data sources. BMC Bioinformatics 2007; 8: 280.
131. Hristova K, White SH. An experiment-based algorithm for predicting the partitioning of unfolded peptides into phosphatidylcholine bilayer interfaces. Biochemistry 2005; 44(37): 12614-9.
132. Jayasinghe S, Hristova K, White SH. Energetics, stability, and prediction of transmembrane helices. J Mol Biol 2001; 312(5): 927-34.
133. Wimley WC, Creamer TP, White SH. Solvation energies of amino acid side chains and backbone in a family of host-guest pentapeptides. Biochemistry 1996; 35(16): 5109-24.
134. Nagarajan V, Kaushik N, Murali B, Zhang C, Lakhera S, Elasri MO, et al. A fourier transformation based method to mine peptide space for antimicrobial activity. BMC Bioinform 2006; 7 (Suppl 2): S2.
135. Yandek LE, Pokorny A, Floren A, Knoelke K, Langel U, Almeida PF. Mechanism of the cell-penetrating peptide transportan 10 permeation of lipid bilayers. Biophys J 2007; 92(7): 2434-44.
136. Yesylevskyy S, Marrink SJ, Mark AE. Alternative mechanisms for the interaction of the cell-penetrating peptides penetratin and the TAT peptide with lipid bilayers. Biophys J 2009; 97(1): 40-9.
137. Grosdidier S, Fernandez-Recio J. Identification of hot-spot residues in protein-protein interactions by computational docking. BMC Bioinformatics 2008; 9: 447.
138. Kortemme T, Baker D. A simple physical model for binding energy hot spots in protein-protein complexes. Proc Natl Acad Sci USA 2002; 99(22): 14116-21.
139. Moreira IS, Fernandes PA, Ramos MJ. Unraveling the importance of protein-protein interaction: application of a computational alanine-scanning mutagenesis to the study of the IgG1 streptococcal protein G (C2 fragment) complex. J Phys Chem B 2006; 110(22): 10962-9.
140. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res 2005; 33(Web Server issue): W382-8.
141. Cheng T, Li X, Li Y, Liu Z, Wang R. Comparative assessment of scoring functions on a diverse test set. J Chem Inf Model 2009; 49(4): 1079-93.
142. Moitessier N, Englebienne P, Lee D, Lawandi J, Corbeil CR. Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. Br J Pharmacol 2008; 153 (Suppl 1): S7-26.
143. Vajda S, Sippl M, Novotny J. Empirical potentials and functions for protein folding and binding. Curr Opin Struct Biol 1997; 7(2): 222-8.
144. Vajda S, Weng Z, Rosenfeld R, DeLisi C. Effect of conformational flexibility and solvation on receptor-ligand binding free energies. Biochemistry 1994; 33(47): 13977-88.
145. Weng Z, Delisi C, Vajda S. Empirical free energy calculation: comparison to calorimetric data. Protein Sci 1997; 6(9): 1976-84.
146. Strockbine B, Rizzo RC. Binding of antifusion peptides with HIVgp41 from molecular dynamics simulations: quantitative correlation with experiment. Proteins 2007; 67(3): 630-42.
147. Audie J. Continued development of an empirical function for predicting and rationalizing protein-protein binding affinities. Biophys Chem 2009; 143(3): 139-44.
148. Audie J. Development and validation of an empirical free energy function for calculating protein-protein binding free energy surfaces. Biophys Chem 2009; 139(2-3): 84-91.
149. Audie J, Scarlata S. A novel empirical free energy function that explains and predicts protein-protein binding affinities. Biophys Chem 2007; 129(2-3): 198-211.
150. Yu L, Yu PS, Yee Yen Mui E, McKelvie JC, Pham TP, Yap YW, et al. Phage display screening against a set of targets to establish peptide-based sugar mimetics and molecular docking to predict binding site. Bioorg Med Chem 2009; 17(13): 4825-32.
151. Kato-Takagaki K, Mizukoshi Y, Yoshizawa Y, Akazawa D, Torii Y, Ono K, et al. Structural and interaction analysis of glycoprotein VI-binding peptide selected from a phage display library. J Biol Chem 2009; 284(16): 10720-7.
152. Barderas R, Desmet J, Timmerman P, Meloen R, Casal JI. Affinity maturation of antibodies assisted by in silico modeling. Proc Natl Acad Sci USA 2008; 105(26): 9029-34.